Company:  GERON CORP (GERN)
Form Type:  SC 13G/A
Filing Date:  2/17/1998 
CIK:  0000886744 
Address:  149 COMMONWEALTH DRIVE
SUITE 2070
 
City, State, Zip:  MENLO PARK, California 94025 
Telephone:  (650) 473-7700 
Fiscal Year:  11/17 
Last Trade
Last Trade: 
$4.19  
Change: 
0.11 (2.70%)  
Trade Time: 
Apr 25  
Market Cap: 
$673.14M
Trade GERN now with 

© 2018  
Description of Business
We are a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data in essential thrombocythemia, or ET, myelofibrosis, or MF, and myelodysplastic syndromes, or MDS, suggest imetelstat may have disease­modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases. On November 13, 2014, we entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which we granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective on December 15, 2014, and we received $35 million from Janssen as an upfront payment.
Register and access this filing in:     
  FORM SC 13G/A